Respiratory
Chronic Asthma
10
Pipeline Programs↗
0
Active Trials↗
5
Companies Involved↗
Chronic Asthma is an early-stage landscape with 10 programs across 5 companies. The most active players are Merck & Co., Pfizer's Upjohn has merged with Mylan to form Viatris Inc., GSK. 1 therapy is approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 24
Analysis
Trial Status
11
clinical trials
Completed8 · 73%
Withdrawn2 · 18%
Terminated1 · 9%
Clinical Trials
Trial Activity
11 trials
Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)
Completed·—·Phase 2·NCT00666679·134 enrolled
Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)
Completed·—·Phase 3·NCT00943397·190 enrolled
The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)
Completed·—·Phase 1·NCT00739297·68 enrolled
Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
Completed·—·Phase 3·NCT00968201·689 enrolled
Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department
Withdrawn·—·N/A·NCT00388739
A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)
Withdrawn·—·Phase 3·NCT00540839
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)